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~ Correlat ions In Pravastatln Treatment Effect 
Between Carotid and Femoral Intima-Medla 
Thickness, and Coronary Artery Stenosls 
Edc de Grcot, J. Wouter Jukema, Aeilko H. Zwinderman, Alexander 
D. Montouban van Swijndregt, Ad J. van Boven, Rob G.A. Ackerst~fl, Anton 
F.W. van der Steen, Ntcofaan Born, Albert V.G. Bruschke, Kong I. Lie. 
REGRESS study group, Utrecht, Netherlands 
The REgression GRowth Evaluation Statin Study (REGRESS) is a two year 
double blind placebo controlled prospective atherosclerosis regression study, 
pdmadly investigating pravastatin treatment effect by means of repeated 
quantitative coronary artsdngraphy (QCA) in a 885 male population with 
anglographicafly proven coronary artery disease. The differences between 
the means of the Mean Coronary ,?-~.=gment Diameter (MSD), and the medians 
of the Minimum Coronary Obstruction Diameter (MOD) showed a significant 
pravasfatin treatment effect (~MSD = 0.04 mm; p = 0.02); 8MOD = 0.06 mm; 
p = 0.001). With a six monthly interval, 255 patients received five B-:'nede 
ultrasound intima-media thickness (IMT) measurements of 16 prespedlied 
carotid and femoral artedal wall segments. Repeated Measurements ANOVA 
of the combined IM'I" data showed a significant pravastatin treatment effect 
on carotid and femoral IMT (p = 0,0024). The coronary and the padpheral 
treatment effects were correlated. 
Results: The treatment effect on IMT (baseline IMT minus IMT dudng 
the iris') was not significantly correlated to the treatment effect on coronary 
diametsr parameters: p > 0.30. 
Conclusion: Pravastatin treatment effect was shown in the coronary arter- 
ies as well as in the carotid and femoral arteries. However, no correlations in 
treatment effect between the coronary and the peripheral artsdes could he 
domoastraled. 
~ Prevalence of  Factor V Leiden Among Women With 
Pulmonary Embol ism or Deep Vein Thrombosis  
During Pregnancy or Oral ContraoBpUve Use 
Denise R. Hirsch, Katdina M. Mikkola, Peter W. Marks, Edward A. Fox, 
Oavid M. Dortman, Bruce M. Ewenstain, Samuel Z. Goldhaber. Brigham 
and Women's Hospital, Harvard Medical School, Boston, MA 
Although Factor V Leiden is associated with an increased risk of venous 
thmmbosts, its frequency has rarely been studied in women with pulmonary 
embolism (PE) or deep venous thrombosis (DVT) during pregnancy, post- 
partum, or oral contraceptive use. Therefore, we determined the prevalence 
of the Factor V Leiden mutation in 50 woman who had suffered prior venous 
thmmboembolism All 50 patients had genetic analysis performed using PCR 
techniques, A functional assay for activated pmtaln C (APC) resistance was 
carded out in women not on anticoagulants at the time of the assay (n = 
30). Ten women (20%) were hetsrozyguus for the mutation (95 CI, 10% to 
34%). Six of these hetsrozygotes (60%) had PE and/or DVT during the first 
trimester, compared with 3 of the 40 women (0%) without he mutation (p = 
0.0009). The functional essay detected APC resistance in 11 (3"/%) of the 
30 women tested, including all 5 hetsrozygutos not on anticoagulants and 
in 6 women with normal Factor V alleles. In this population, the functional 
assay was 100% sensitive and 76% specific for the genetic mutation. During 
pregnancy or oral contraceptive use, functional APC resistance may occur 
in the absence of Factor V Leiden. Both APC resistance and the Factor V 
Leiden mutation appear to be associated with an increased dsk of PE or 
DVT dudug pregnancy or oral contraceptive i,e. The close association be- 
tween first trimester PE and Factor V Leiden suggests that screening for this 
mutation may be warranted, in women at high dsk of PE or DVT who are 
considering becoming pregnant, 
~ ' ~  Proteln C Resistance In Severe Peripheral 
A lheroecleros is  and in Unherslded Myocerdis l  
Infarction 
Felicita Andreotti, Ralmondo De Cdslofaro, Giuseppe Patti, Carol 
C. Shoulders, Sarah E. White, Mary Giifigan, Willy van de Graef, 
Anne Bradshaw, Graham J. Davies, Attillo Mased, Catholic University, 
Rome, #a/y; RPMS, London, UK 
Activated protein C (APC) inhibits coagulation factors V and VIII. APC dis- 
function has been hypothesized in atheroma nd thrombus development, but 
published data are discordant. Analysis of the Arg506- > Gin mutation of 
the factor V gene. held responsible for APC resistance, and the use of cut-off 
values in functional tests may have underestimated APC abnormalities. To 
assess its possible mlo in atherosctemsis and thrombosis, we investigated 
functional APC resistance in pts with severe peflpheral atherosclerosis but 
no previous thrombeembolism (PVD, n = 39, 41-66 yra) or with previous 
unheralded myocardial infarction (MI, n = 41, 34-64 yrs) and in 47 matched 
healthy controls (CTR, 39-67 yts). Pts were < 60 yrs at diagnosis. APC 
resistance was assessed as the ratio o1 aPTT + APC (0.7 mg/L) over aPTr 
without APC - -  a lower ratio indicating reater resistance. No cut-off value 
was used. In no case were plasma protein S levels < 20%-- known to affect 
APC resistance. Plasma fibdnugen and thrombin-antithmmbin III (TAT) levels 
were also measured. Results are medians with interquartiles: 
PVO pts MIt~s CTR 
APC resistance 3.8 (3.2-4.8)" 4.1 (3.5-4.6)** 4.6 (3.9-5.2) 
Rbflnogen, g/L 2.7 (2.5-3.1)" 2.8 (2.5-3.1)o* 2.5 (2.3-2.8) 
TAT, pg/L 4.3 (2.7-10) 3.6 (2.5-6.6) 4.5 (3-9) 
*p < 0.02 and °*p < 0.01 vs CTR. 
NO significant relation was found between APC resistance and fibrinogen 
or TAT. 
Thus, both PVD and MI patients have signif'cantly greater APC resistance 
compared with healthy controls, as assessed by a global functional assay. 
The data suggest that impaired natural antiso~gulation by protein C, in 
addition to raised fihdnogen, may be a dsk factor for athemsclerosis and 
arterial thrombosis. 
~ UI lmsound Guided Closure o f  False Aneurysms by 
Injecting Biodegradable Bovine Collagen 
Sjef M.P.G. Ernst, Egbert T. BOl, Wybren Jaarsma, E. Gijs Mast, 
Maarten-Jan Suttoq0, Frans L Moll1, H.W, Thijs Plokker. 1 Departments of 
Interventional Cardiology and Vascular Surgery; St. Antonius Hospital, 
N/euwege/n, NL 
Although the prevalence of false aneurysma fter artsfial catheterization may 
be diminishing due to smaller devices, opt(realization of the anticoagufation 
and new ctosure devices, it is not to be expected that this complication will 
be eradicated totally in the future. 
Until now it is generally accepted that surgical closure is the treatment of 
choice, when (ultra sound guided) compression has been ineffective. Previ- 
ously we reported on closure of false aneurysma by insertion of long f~reus 
biodegradable bovine collagen plugs into the cavity. The long collagen fibre 
bundles promote the natural coagulation cascade within the false aneurysm. 
Although more than hundred patients with large false aneurysms have been 
treated successfully without complications, the procedure requires consider- 
able skill. On average 10 to 30 collagen plugs have to be inserted through 
a large cat,re (12F) sheath and an additional puncture in the contralateral 
groin is performed for anglographical verifcaUon of the closure. 
To facilitate application of collagen, a hiahly viscous and cohesive pasts 
was developed by suspending the long COllagen fibres in water. This collagen 
paste is injected through a 6F canala into the centre of the aneurysm under 
guidance of duplex scanning. 3 to 6 cc of the cohesive paste is injected into 
the cavity of the false aneurysm. 6 Patients have been treated successfully 
without complications and good results at short-tenn follow up as assessed 
by duplex scanning. 
We conclude that false aneuWsma can be dosed easily and safely by 
injecting a suspension of biodegradable bovine collagen into the aneuwsro 
under duplex guidance. 
~ Elevated Plasma Homecysteine: A Common 
Reversible Risk Factor for  Thromboembol lsm in 
Men and Women 
Anjan Gupta, Kaedice Kottke-Marchant, Mlohelle 3esic, Donald 
W. Jacobsen, Ralph Green, Kill(an Robinson. The Cleve~+nrl C inic 
Foundation, Cleveland, Ohio 
Back qTound: High plasma homocystalne is a dsk factor for atheroscterosis 
but the relationship between homocyeteine and thrombosis in the presence 
of a normal hypemoagulalion profile is unknown. 
Methods: Fasting homocystsine concentrations were determined in 60 
patients (37 men, 23 woman, age 46 ::1:12 yrs) with thmmbesis and were 
compared with healthy age and sex matched controls. All patients had nega- 
tive screening tests for hypercoagulability. The 951h percentile (17.9 mmol/L) 
in controls was taken as a cut point to define a high homocysteine concen- 
tration (HHE). 
Results: Mean homocysteine concentrations were higher in cases than 
controls (21.3 + 13.8 vs 11.0 4. 4.7 mmol/L, p < 0.001). Concentrations were 
higher both in male (22.9 4. 13.6 vs 11.7 + 3.4 mmol/L, p < 0.001) and in 
fer~ats cases (20.1 4.14.2 vs 9.7 :t: 6.2 retool/L, p < 0.01), when compared 
to gender-matched controls. 
